HomeNVAX • NASDAQ
Novavax Inc
add
$6.86
0.29%
Pre-market:(0.29%)+0.020
$6.88
Closed: Dec 5, 8:11:28 AM UTC-5 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 70.45M | -16.64% |
Operating expense | 46.12M | -42.92% |
Net income | -202.38M | -66.84% |
Net profit margin | -287.29 | -100.16% |
Earnings per share | -1.25 | -64.47% |
EBITDA | -72.80M | 37.84% |
Effective tax rate | 0.32% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 762.89M | -16.12% |
Total assets | 1.18B | -31.10% |
Total liabilities | 1.34B | -40.30% |
Total equity | -156.67M | — |
Shares outstanding | 162.50M | — |
Price to book | -7.13 | — |
Return on assets | -15.77% | — |
Return on capital | -110.07% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -202.38M | -66.84% |
Cash from operations | 107.80M | 174.44% |
Cash from investing | -136.53M | -527.83% |
Cash from financing | 42.44M | 43,854.64% |
Net change in cash | 14.38M | 113.44% |
Free cash flow | 96.84M | 223.39% |
Previous close
$6.84
Day range
$6.73 - $6.87
Year range
$5.01 - $11.50
Market cap
1.11B USD
Avg Volume
3.89M
P/E ratio
3.81
Dividend yield
-
Primary exchange
NASDAQ
About
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's first and only commercial product is the Novavax COVID-19 vaccine. The company is also developing vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax also develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Founded
1987
Headquarters
Website
Employees
952
